Benign Prostatic Hyperplasia (BPH) Clinical Trial
Official title:
Exploratory Study of L.S.E.S.r. (PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in the Treatment of Urinary Symptoms Related to BPH; a Multinational, Multicentric, Randomised, Double Blind Parallel-group Prospective Study
Inflammation is reported as one of the most recent hypotheses to explain BPH. Recent
published works pointed out that urine and serum markers could be used for detection of
prostatic inflammation.
The aim of the study is to assess the activity on inflammation biomarkers (serum and urine
inflammation markers) of Permixon® 160 mg hard capsule and Tamsulosine Arrow LP in the
treatment of urinary symptoms related to BPH.
The potential links between serum and urinary markers of inflammation and BPH clinical
symptoms at baseline and on treatment will be explored.
n/a
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03052049 -
Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres
|
N/A | |
| Recruiting |
NCT04757116 -
Post-Market Study to Assess iTind Safety in Comparison to UroLift
|
N/A | |
| Completed |
NCT03460873 -
Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate
|
||
| Completed |
NCT01218243 -
An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia
|
Phase 2 | |
| Completed |
NCT01566292 -
Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT00407953 -
PROLIEVE® Post-Marketing Study TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)
|
Phase 4 | |
| Completed |
NCT03191734 -
French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
|
N/A | |
| Recruiting |
NCT04838769 -
REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men
|
N/A | |
| Completed |
NCT03856242 -
Benign Prostatic Hyperplasia and Ischemic Heart DIsease
|
Phase 4 | |
| Completed |
NCT04032067 -
Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
| Completed |
NCT02505919 -
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
|
N/A | |
| Completed |
NCT02855892 -
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
|
Phase 2 | |
| Completed |
NCT02145208 -
Study to Assess the Efficacy of Medi-Tate iTind Device
|
N/A | |
| Completed |
NCT00970632 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
|
Phase 3 | |
| Recruiting |
NCT02592473 -
Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia
|
N/A | |
| Completed |
NCT00945490 -
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
|
Phase 3 | |
| Completed |
NCT00759135 -
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
|
Phase 2 | |
| Completed |
NCT00224107 -
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
|
Phase 3 | |
| Recruiting |
NCT04648176 -
Application of MOSES Technology in BPH
|
N/A | |
| Terminated |
NCT00651807 -
A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)
|
Phase 2 |